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Abstract
Peripheral neurotoxicity is one of the most distressing side effects of oxaliplatin therapy for
cancer. Indeed, most patients that received oxaliplatin experience acute and/or chronic
severe sensory peripheral neuropathy. However, despite similar co-morbidities, cancer
stage, demographics and treatment schedule, patients develop oxaliplatin-induced periph-
eral neurotoxicity with remarkably different severity. This suggests individual genetic vari-
ability, which might be used to glean the mechanistic insights into oxaliplatin neurotoxicity.
We characterized the susceptibility of different mice strains to oxaliplatin neurotoxicity inves-
tigating the phenotypic features of neuropathy and gene expression profiles in dorsal root
ganglia of six genetically different mice strains (Balb-c, C57BL6, DBA/2J, AJ, FVB and CD1)
exposed to the same oxaliplatin schedule. Differential gene expression in dorsal root ganglia
from each mice strain were assayed using a genome-wide expression analysis and selected
genes were validated by RT-PCR analysis. The demonstration of consistent differences in
the phenotypic response to oxaliplatin across different strains is interesting to allow the
selection of the appropriate strain based on the pre-defined read-out parameters. Further
investigation of the correlation between gene expression changes and oxaliplatin-induced
neurotoxicity phenotype in each strain will be useful to deeper investigate the molecular
mechanisms of oxaliplatin neurotoxicity.
Introduction
Oxaliplatin is a 3rd generation compound of the platinum drug family effectively employed for
the treatment of colorectal cancer, the third leading cause of death in western countries. Even
if earlier diagnosis and aggressive cancer treatment allow a longer life expectancy, long-term







Citation: Marmiroli P, Riva B, Pozzi E, Ballarini E,
Lim D, Chiorazzi A, et al. (2017) Susceptibility of
different mouse strains to oxaliplatin peripheral
neurotoxicity: Phenotypic and genotypic insights.
PLoS ONE 12(10): e0186250. https://doi.org/
10.1371/journal.pone.0186250
Editor: Simon Beggs, University College London,
UNITED KINGDOM
Received: June 30, 2017
Accepted: September 27, 2017
Published: October 11, 2017
Copyright: © 2017 Marmiroli et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This work was supported by Fondazione
Cariplo [Grant ID 2013-0842], www.
fondazionecariplo.it (PM); and Associazione Italiana
per la Ricerca sul Cancro (AIRC) [Trideo
(Transforming Ideas in Oncological Research)
Grant ID 15942], www.airc.it (VAC). The funders
had no role in study design, data collection and
treatment-related side effects can severely compromise patients’ quality of life after oxaliplatin
treatment. Since oxaliplatin preferentially damages the peripheral sensory fibers and dorsal
root ganglia (DRG) neurons [1], which lack the protection of the blood brain barrier, one of
the most debilitating side effects of oxaliplatin-based regimens is peripheral neurotoxicity.
Oxaliplatin treatment produces an acute and transient neuropathy (rate up to 90%) with neu-
ropathic pain elicited by exposure to cold and a chronic sensory syndrome (rate 40–80%) with
similar, but enduring characteristics complicated by nerve functional impairment and struc-
tural degeneration [2–7]. The exact mechanisms underlying oxaliplatin-induced neurotoxicity
(OIPN) remain poorly understood. Alterations in ion channels and calcium signalling, oxida-
tive stress, mitochondrial failure and drug membrane transporters are only some of the most
studied mechanisms of OIPN [8, 9]. Despite similar co-morbidities, demographic profile, can-
cer stage and treatment schedule, oxaliplatin-treated patients can develop OIPN with different
severity [10]. Individual variability in drug toxicity response has suggested that specific genetic
variants determining over-expression or down-regulation of genes involved in drug disposi-
tion, metabolism, detoxification, channels functioning and DNA repair could be associated
with OIPN susceptibility and severity [11–16], but this still remains a matter of scientific
debate [5, 17, 18].
This variability can also be observed in animal models of chemotherapy-induced peripheral
neurotoxicity, where genetic variations between mice strains can influence response to drug
treatment and determine different toxicity phenotypes [19, 20].
In this study, we tested the different susceptibility to oxaliplatin neurotoxicity through a
phenotypic characterization of OIPN in several inbred and one outbred strains of mice. Inbred
strains, generated by sib mating for at least 20 generations, are useful in determining the
genetic contribution to variability because they are virtually isogenic (i.e., genetically identical).
Outbred mice, on the other hand, are a closed population of mice maintained for high hetero-
zygosity for at least 4 generations [21]. Using both inbred and outbred animals, we searched
for a low intra-strain variability preserving the possibility of inter-strains differences. The
whole gene expression profile in DRG was then assessed to identify a possible correlation
between the severity of OIPN and a particular pattern of gene expression modulated by the
drug.
This is the first preclinical study aiming at characterizing the susceptibility of different mice
strains to oxaliplatin neurotoxicity and correlating it with gene expression study. Significant
phenotypic differences in oxaliplatin induced neurotoxicity were demonstrated among strains.
Genetic characterization evidenced some gene expression changes that can be considered a




Three-hundred and thirty-six mice belonging to 1 outbred (CD1) and 5 different inbred
(Balb-c, C57BL65, DBA/2J, AJ, FVB) strains aged 10 weeks upon arrival were employed
(Envigo, San Pietro al Natisone, Italy).
Animals were housed 5 per cage in a limited access animal facility where room temperature
and relative humidity were set at 20 ± 2˚C and 55 ± 10% respectively. Artificial lighting pro-
vided a 12 h light/12 h dark (7 a.m.–7 p.m.) cycle. Treated and untreated mice were housed
separately. The general condition of the animals was assessed daily.
The care and husbandry of animals were in conformity with the institutional guidelines in
compliance with national (D. L.vo 26/2014, Gazzetta Ufficiale della Repubblica Italiana, n.61,
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March 14th 2014) and international laws and policies (European Union directive 2010/63/UE;
Guide for the Care and Use of Laboratory Animals, U.S. National Research Council, 1996).
The Ethics Committee of the University of Milan Bicocca approved the study plan (n. 004874/
14).
All mice were euthanized at the end of the experimental period under deep isoflurane-
induced anaesthesia.
Anaesthesia and euthanasia
For the recordings in the peripheral nerves and in the spinal cord dorsal horn, anaesthesia was
induced in a chamber with 3% isoflurane carried in oxygen followed by 1–1.5% isoflurane by
nose cone for maintenance during the procedures. The corneal blink response and any with-
drawal physical response to external stimuli were adequately suppressed. To avoid isoflurane-
induced hypothermia, the body temperature was maintained at ~37˚C using a heating pad
(Homoeothermic System, Harvard Apparatus, Holliston, MA).
At sacrifice, animals were deeply anesthetized with isoflurane and exanguinated by caval
vein puncture.
Drug
Oxaliplatin (a gift of Debiopharm, Lausanne, Switzerland) solution was prepared as reported
by Renn and collaborators [1]. Briefly, oxaliplatin was dissolved in 5% glucose immediately
before each administration. It was injected intravenously at the dose of 3.5 mg/kg (10 ml/Kg).
Using Du Bois’s formula to calculate human body surface area, this dose is equivalent to 130
mg/m2 per administration and a cumulative dose of 1080 mg/m2 after 8 cycles.
Experimental design
Mice of each strain were randomized into a total of 12 groups of 28 animals each. For each
strain 28 animals were injected intravenously in the tail vein with oxaliplatin 3.5 mg/Kg (10
ml/Kg) twice a week for 4 weeks (cumulative dose of 28 mg/Kg), and 28 mice were left
untreated (naive). Twenty animals (10 naive +10 oxaliplatin-treated) for each strain were
employed for neurophysiology, pain behaviour assessment, morphological and morphometric
analysis and for platinum concentration. The pool of DRG from other 16 animals (8 naive + 8
oxaliplatin-treated) of each strain were processed for the molecular analysis of gene expression.
An independent cohort of 20 animals for each strain (10 naive + 10 oxaliplatin-treated) under-
went the electrophysiological analysis in the dorsal horn of the spinal cord (Table 1).

















Balb-c (10+10) (8+8) (10+10) (28+28)
C57BL6 (10+10) (8+8) (10+10) (28+28)
A/J (10+10) (8+8) (10+10) (28+28)
FVB (10+10) (8+8) (10+10) (28+28)
DBA/2J (10+10) (8+8) (10+10) (28+28)
CD1 (10+10) (8+8) (10+10) (28+28)
The table shows a summary of animals employed for each mice strain and the analysis performed in the study (OHP = oxaliplatin).
https://doi.org/10.1371/journal.pone.0186250.t001
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Neurophysiological analysis was performed to assess the functionality of peripheral
nerves at baseline and at the end of oxaliplatin treatment (week 4). Neuropathic pain was
evaluated at baseline, week 2 and week 4 through behavioural tests for cold (acute OIPN) and
mechanical (chronic OIPN) thresholds. At week 4, the electrical activity of spinal cord wide
dynamic range neurons was determined as a quantitative measure of central nervous system
sensitization.
After in vivo evaluations, mice were sacrificed for biological sampling: skin biopsy was pro-
cessed for the evaluation of intraepidermal nerve fibers (IENF) density, caudal and sciatic
nerves were harvested for morphological observations and DRG for morphological, morpho-
metric and gene expression analysis of gene arrays and Real Time PCR. Platinum concentra-
tion was measured in DRG, sciatic nerve and plasma by atomic absorption spectrometry.
In full respect of the Reduction principle of the 3Rs, the number of animal/group (N = 28)
was selected to obtain reliable results and enough biological samples to perform the analysis
planned. Moreover, in agreement with the Refinement principle, the choice to perform
electrophysiological measurements under general anaesthesia reduced to minimum the animal
suffering and stress, obtaining less variable data and minimizing the number of necessary
animals.
Characterization of OIPN phenotype in mice
Clinical monitoring and body weight. Mice were observed daily for any evident symp-
toms of sickness. Changes in their appearance (e.g., kyphosis and altered grooming), behaviour
(altered nesting) and activity (altered exploring) were monitored. Body weight was recorded
twice weekly for general toxicity assessment and drug doses adjustment.
Neurophysiology. Forty-eight hours after the end of oxaliplatin treatment, mice were
tested for their nerve functionality. Neurophysiology was performed in the caudal and the digi-
tal nerves using an electromyography apparatus (Myto2 ABN Neuro, Firenze, Italy) as previ-
ously reported [1, 22–24]. Nerve Conduction Velocity (NCV) was measured by placing a
couple of needle recording electrodes (cathode and anode) at the base of the tail (for caudal
recordings) or at the ankle bone (for digital recordings) and a couple of stimulating electrodes
3.5 cm far from the recording points (for caudal recordings) or close to the fourth toe (for digi-
tal recordings). The NCVs were calculated as a ratio between the latency between the stimulus
artifact and the onset of the first peak of the elicited action potential and the distance between
the recording and the stimulating points. Intensity, duration and frequency of stimulation
were set up in order to obtain optimal results. Averaging technique was applied carefully and
only when appropriate. For sensory recordings filters were kept between 20 Hz and 3KHz and
sweep was kept at 0.5 msec. For both nerves orthodromic stimulation was selected in order to
avoid artifacts due to motor activation (particularly in the caudal nerve).
All the neurophysiological measures were obtained under standard conditions in a temper-
ature/humidity controlled rooms. The baseline recordings were performed before starting the
drug treatments in order to randomize animals into homogeneous groups. The changes were
analysed for significant differences between 2 groups (oxaliplatin-treated vs. naive) of each
strain by Student t-test considering p<0.05 as statistically significant.
Behavioral tests. At baseline and 24 hours after the 4th and the 8th oxaliplatin treatment,
mice were tested for their cold and mechanical thresholds. The cold nociceptive threshold was
assessed 24 hours after oxaliplatin, as an indicator of acute response to treatment by using the
Cold Plate (model 35100—Hot/Cold Plate, Ugo Basile Biological Instruments, Comerio, Italy)
composed by a Plexiglas cylinder and a thermostatic plate, able to reach variable temperatures.
Mice were placed on the plate fixed at +4˚C, free to move and walk. The number of pain
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signs/suffering (rear licking and shaking, jumping, alterations in rear and tail movements)
were recorded by a blind examiner in a trial of 5 minutes. The trial was anyway terminated if
mice prematurely showed a strong intolerance to temperature (evident as anxiety, several
changes in the normal behaviour and movements, vocalization).
The mechanical threshold was used to quantify the chronic pain induced by oxaliplatin,
using the Dynamic Aesthesiometer (model 37450, Ugo Basile Biological Instruments,
Comerio, Italy), which generated a linearly increasing mechanical force. Before testing, ani-
mals were placed in a Plexiglas chamber (28 x 40 x 35-cm, wire mesh floor) in the Dynamic
Aesthesiometer for a 2 hours acclimatization period. At each time point, a servo-controlled
mechanical stimulus (a pointed metallic filament, 0.5 mm diameter) was applied to the plantar
surface of the hind paw, which exerted a progressively increasing punctuate pressure, reaching
up to 15g within 15 sec. The pressure evoking a clear voluntary hind-paw withdrawal response
was recorded automatically and represents the mechanical nociceptive threshold index. The
mechanical threshold was expressed as a mean value of 3 measures per hind paw, recorded
alternatively every 2 minutes. These results represent the maximal pressure (expressed in
grams) tolerated by the animals. The cut-off was set at 30 sec, after which the mechanical stim-
ulus was automatically stopped.
The changes were analysed for significant differences between 2 groups (oxaliplatin-treated
vs. naive) of each strain by Student t-test considering p<0.05 statistically significant.
Spinal cord electrophysiology. Extracellular electrophysiological recording was per-
formed to measure the activity of wide dynamic range neurons in the spinal dorsal horn as
previously described [1, 23]. Briefly, 24 hours after the end of oxaliplatin treatment, mice
underwent a laminectomy at the level of the T13-L2 vertebrae, to expose the L4-L5 spinal seg-
ment. Dura madre was carefully removed and a tungsten microelectrode (10 μm-tip, Frederick
Haer Co., Brunswick, ME, USA) was vertically positioned with an electronical micropositioner
at 400–600 μm in depth in the dorsal horn (Model 660 micropositioner, David Kopf Instru-
ments, Tujunga, CA, USA). SciWorks (Datawave Technologies, Loveland, CO, USA) was used
to acquire and digitalize the neuronal electrical activity during spontaneous and evoked
response by light tactile (sable-hair brush), moderate noxious tactile (press) and thermal (ace-
tone drop) stimulation of the plantar surface of the hindpaw ipsilateral to the electrode posi-
tion. The signals were amplified and filtered using standard electrophysiological techniques.
To optimize the amplitude of an identified neuron, the electrode was moved in the dorsal-ven-
tral plane. Neuronal activity was discriminated, sorted and analysed by principal components
analysis offline using SciWorks (v7.0, Datawave Technologies, Berthoud, CO, USA). Stimulus-
evoked activity was quantified by calculating the number of spikes/seconds.
The changes were analysed for significant differences between 2 groups (oxaliplatin-treated
vs. naive) of each strain by Student t-test considering p<0.05 statistically significant.
Neuropathology: Morphological and morphometric assessments. L4-L5 DRG, left sci-
atic nerves at mid-thigh and caudal nerves at 1 cm far from the base of the tail were dissected
out without stretching at sacrifice (48 hours after the last oxaliplatin injection) and fixed by
immersion in 2% glutaraldehyde/4% paraformaldehyde or 3% glutaraldehyde in 0.12 M phos-
phate buffer solutions, respectively. Samples were then post-fixed in OsO4, epoxy resin-
embedded and used for light microscopy evaluations and morphometric analysis. Semi-thin
sections (1 μm) were prepared, stained with toluidine blue and examined with a Nikon Eclipse
E200 light microscope (Leica Microsystems GmbH, Wetzlar, Germany) [22, 25]. Serial 1-μm
sections, spaced 50 μm, were prepared for the DRG morphometric analysis. Images were cap-
tured with a light microscope-incorporated camera (Leica DFC 280 Wetzlar, Germany) at a
magnification of 20x. The somatic, nuclear and nucleolar size of at least 200 DRG neurons/ani-
mal were manually measured and analysed with a computer-assisted image analyser (Image J
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software, US National Institutes of Health). The same blinded observer performed all the mor-
phometric measurements [22, 24].
The changes were analysed for significant differences between 2 groups (oxaliplatin-treated
vs. naive) of each strain by Student t-test considering p<0.05 statistically significant.
IENF density assessment. At sacrifice hind paw skin specimens were collected and pro-
cessed as previously described [26]. Briefly, glabrous skin punches from the plantar hindpaw
were fixed in 2% paraformaldehyde-lysine and periodate sodium for 24 h at 4˚C, cryoprotected
and serially cut to obtain 20 μm-thick sections. Sections were immunostained with rabbit poly-
clonal anti-protein gene product 9.5 (PGP 9.5; Bio-Rad Company, AbD Serotec) using a free-
floating protocol. The same blinded observer counted the total number of PGP 9.5-positive
IENF crossing the dermal–epidermal junction under a light microscope at 40X magnification
(Nikon Eclipse E200 light microscope, Leica Microsystems GmbH, Wetzlar, Germany). The
linear density of the IENF/mm was calculated [27] accordingly to the length of the epidermis
analysed (Microscience Inc., Seattle, WA, USA).
The values were presented as a rate change of oxaliplatin groups compared to their respec-
tive naive animals. The changes were analysed for significant differences between 2 groups
(oxaliplatin-treated and naive) of each strain by Student t-test considering p<0.05 statistically
significant.
Platinum concentrations. The total platinum concentration was determined as previ-
ously reported by Canta and collaborators [28] on frozen sciatic nerve, DRG, and plasma
obtained from 3 animals/group/strain at sacrifice. Frozen samples underwent a digestion pro-
cess with a HNO-HCL solution and analysed by “Atomic Absorption” (Analyst 600 Perkin
Elmer, Monza, Italy). Platinum concentration (μg/g tissue or μg/ml plasma) was calculated
accordingly.
Genotype evaluation: Gene expression analysis
Microarray. Gene expression profiling was evaluated for 48 samples from 4 different
mouse strains (Balb-c, C57BL6, AJ and CD1). Briefly, total RNA was isolated from sections of
frozen DRG from 12 animals (6 animals injected with oxaliplatin 3.5 mg/Kg for 4 weeks and 6
animals untreated) for each strain, using TriReagent1 (Sigma, St. Louis, MO, USA). DRGs
from each animal were pooled together but each animal was maintained separate for the
microarray experiments (i.e. 6 microarrays in the treated group and in the untreated group
were analysed for each strain). RNA quantity was evaluated by Bioanalyzer 2100 (Agilent
Technologies, Palo Alto, CA, USA). Following the isolation procedure, mRNA was amplified
starting from 5 μg of total RNA using MessageAmp aRNA Amplification kit (Ambion Inc.,
Austin, TX, USA). Amino-allyl modified nucleotides were incorporated during the overnight
in vitro transcription step according to the manufacturer’s protocol. Labeling was performed
using NHS (N-hydroxysuccinimidyl) ester Cy3 or Cy5 dyes (GE Healthcare Europe GMBH,
Upsala, Sweden) able to react with the modified RNA. At least 5 μg of aaRNA for each sample
were labeled and then purified with columns; 0.75 μg of labeled aaRNA for each sample were
then hybridised. The Dye-Swap replication procedure was applied, in order to increase accu-
racy. Samples were hybridised on 60K mouse oligo-glass arrays (Agilent Technologies, Santa
Clara, California, USA). Arrays were scanned by Agilent scanner. Images obtained were ana-
lysed by the Feature Extraction software Agilent (version 9.5) and the text files were then pro-
cessed using the Bioconductor package Limma (Linear models for microarray analysis). Two-
class comparison analysis were performed using the moderated t-statistic available within the
Limma package [29]. P-values were adjusted for multiple testing by using a false discovery rate
(FDR) correction [30]. Analysis then proceeded as described in the main text.
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Real time quantitative PCR (qRT-PCR). Total RNA was isolated from sections of frozen
DRG from 72 animals using TRI-Reagent1 (Sigma Aldrich Inc., Milan, Italy). Specifically, for
each strain, 6 control and 6 treated animals were used. mRNA from different animals was not
pooled and therefore each mRNA was analysed separately. Im-Prom-II™ Reverse Transcriptase
(Im-Prom-II™ Reverse Transcription System, Promega, WI, USA) was used to generate cDNA
using 1 μg of RNA and oligo dT primers, according to the instructions of the manufacturer.
Reverse transcription was performed using a thermal-cycler (Eppendorf, Hamburg, Germany)
and the following heating protocol: 10 minutes at 25˚C, 45 minutes at 42˚C and 5 minutes at
99˚C. cDNA was then stored at -20˚C until further used. qRT-PCRs were performed on a
96-well plate, in triplicate, and florescence intensity assessed using the CFX96™ Real-Time
PCR Detection Systems (Bio-Rad Inc., Milan, Italy). The following conditions were adopted:
12.5 μL Maxima™ SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientific Inc., Milan,
Italy), 0,1 μM of forward and reverse primers, and 5 μL of 1:5 diluted cDNA, in a total volume
of 25 μL/reaction. The list of primers used is in S1 Table. Transcripts were normalized to the
expression of Ribosomal Protein S18 mRNAs, assessed using the 5’-TGCGAGGTACTCAACA
CCAACA-3’ FW and 5’-CTGCTTTCCTCAACACCACA-3’RV primers (Sigma-Aldrich
Inc., Milan, Italy), 60˚C annealing temperature. For each gene, the threshold cycle (Ct) was cal-
culated using CFX Manager Software (Bio-Rad Inc., Milan, Italy) by determining the cycle
number at which the change in the fluorescence of the reporter dye crossed the threshold. The
Ct of treated cells was compared to the Ct generated by the control cells and ΔCt was calculated
as the difference between Ct values, determined using the equation 2-ΔCt.
Results
Acute and chronic oxaliplatin neurotoxicity
Oxaliplatin chronic treatment was generally well tolerated by the animals of all strains. Mice
continued to groom, eat, drink and explore their surroundings. No animal died during the
treatment, body weight loss was below 10% (data not presented) and only approximately 20%
of animals showed signs of mild kyphosis and piloerection.
The acute symptoms of neurotoxicity were assessed by Cold Plate test.
Then, we employed neurophysiological and behavioural analysis, neuropathological evalua-
tions of the DRG, sciatic and caudal nerve and morphometric measures of DRG sensory neu-
rons and of IENF to study the extent of functional and structural damages induced by chronic
oxaliplatin treatment.
Cold Plate test. Beyond the chronic functional and structural abnormalities in the periph-
eral nervous system, oxaliplatin treatment firstly caused an acute hypersensitivity to cold expo-
sure within 48 hours after infusion. To determine whether different strains differently exhibit
signs of cold hyperalgesia, mice were tested for their responses to cold stimulations at baseline
(day 1), 24 hours after the 4th (day 13) and 24 hours after the 8th oxaliplatin injection (day 26).
Cold hyperalgesia was defined as an increase in the sensitivity of animals to a nociceptive cold
temperature (+4˚C) recorded as a number of events related to pain (jumping, licking etc.) in a
given time. Twenty-four hours after the last oxaliplatin injection Balb-c, AJ and FVB, but not
C57BL6, DBA/2J and CD1 mice had a statistically significant increase of the number of events
related to pain 24 hours after oxaliplatin injection (80.6%, p<0.001 vs NAIVE for Balb-c;
31.9%, p = NS for C57BL6; 51.5%, p<0.01 vs NAIVE for FVB; 165%, p<0.0001 vs NAIVE for
AJ; 3.1%, p = NS for DBA/2J and 19.6%, p = NS for CD1). (Fig 1).
Neurophysiology. To assess the functional status of peripheral nerves, NCVs were mea-
sured in the caudal and digital nerves 3 days after the last oxaliplatin dose. Table 2 shows the
mean NCV values (± SD) of oxaliplatin-treated groups and their naive counterparts, the rate
Oxaliplatin neurotoxicity in different mouse strains
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Fig 1. Cold Plate test. The graphs report the number of events related to pain (withdrawal response) during thermal (cold)
stimulation of oxaliplatin-treated animals versus naive animals at baseline, day 13 and day 26.
https://doi.org/10.1371/journal.pone.0186250.g001
Oxaliplatin neurotoxicity in different mouse strains
PLOS ONE | https://doi.org/10.1371/journal.pone.0186250 October 11, 2017 8 / 25
change of treated animals compared to untreated mice and the statistical analysis. Only Balb-c
and FVB mice showed a statistically significant reduction of both caudal and digital NCV
(Balb-c: -13% and -14.7% for caudal and digital respectively, p<0.0001 vs NAIVE; FVB:
-12.6% and -13% for caudal and digital respectively, p<0.001 vs NAIVE). Oxaliplatin-treated
DBA/2J showed a significant 8% decrease in the caudal NCV (p<0.001 vs NAIVE) while only
digital NCV was decreased in CD1 mice (-22%, p<0.0001 vs NAIVE). No significant func-
tional changes were recorded in the peripheral nerves of C57BL6 and AJ mice.
Morphological analysis of DRG, sciatic nerve and skin biopsies. Next, we examined
structural changes in DRG, sciatic and caudal nerves and in unmyelinated fibers of the skin. In
Fig 2 we reported representative pictures of DRG (A-B), peripheral nerves (caudal nerves, C-D
and sciatic nerves, E-F) and skin biopsies (G-H) of Balb-c mice. Oxaliplatin caused typical
morphological alterations in DRG sensory neurons at the light microscope, as previously
reported [1, 31] [32]: the increased incidence of multiple and eccentric nucleoli (Fig 2B) was
evident in treated animals compared to naive (Fig 2A). A moderate number of degenerating
nerve fibers (Fig 2D) and a slight fiber loss were observed in the caudal nerve of Balb-c mice
treated with oxaliplatin. Degenerating fibers (Fig 2F), indicative of a slight axonopathy, were
evident in sciatic nerves of Balb-c animals treated with oxaliplatin compared to their naive (Fig
2C and 2E). Very mild myelin derangement (Fig 2F) represented by uncompacted sheats was
only occasionally seen. The morphological aspect of the unmyelinated fibers in the skin biop-
sies (IENF) was normal, despite a severe reduction in their density (Fig 2H), in animals treated
with oxaliplatin compared to the naive (Fig 2G). Similar, but milder, changes were evident in
the other strains.
Morphometric analysis of DRG neurons. To further investigate the structural changes in
the DRG, we performed a morphometric analysis of DRG neurons. The mean values (± SD) of
somatic, nuclear and nucleolar areas of oxaliplatin-treated groups and their naïve counter-
parts, the rate change of treated animals compared to the untreated mice and the statistical
analysis can be found in Table 3. The results of this quantitative analysis support the
Table 2. Nerve Conduction Velocity (NCV).
CAUDAL NCV (m/sec)
NAIVE OHP CHANGE vs NAIVE (%)
Balb-c 27.1±0.37 23.6±0.40 (***) -13.0
C57BL6 26.7±0.42 26.3±0.48 -1.6
AJ 21.8±0.44 22.1±0.56 1.4
FVB 29.1±0.59 25.5±0.63 (**) -12.6
DBA/2J 28.3±0.27 26.0±0.45 (**) -8.0
CD1 25.4±0.33 24.0±0.58 -5.4
DIGITAL NCV (m/sec)
NAIVE OHP CHANGE vs NAIVE (%)
Balb-c 28.5±0.51 24.3±0.53 (***) -14.7
C57BL6 27.2±0.56 27.2±0.57 -0.3
AJ 25.6±0.96 23.2±0.85 -9.3
FVB 28.8±0.65 25.0±0.49 (**) -13.0
DBA/2J 27.0±0.66 28.0±0.82 3.5
CD1 25.1±0.80 19.5±0.35 (***) -22.0
***p<0.0001 vs NAIVE;
**p<0.001 vs NAIVE; Student t test
https://doi.org/10.1371/journal.pone.0186250.t002
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neurophysiological data: only oxaliplatin-treated Balb-c and FVB mice showed a severe and
statistically significant reduction in size of all the neuronal structures compared to their naive
counterparts (Balb-c: -12.6%, p<0.001 vs NAIVE for somatic area, -11.9% and -31.8%,
p<0.0001 vs NAIVE for nuclear and nucleolar areas; FVB: -9.9% and -12.9% p<0.001 vs
Fig 2. Morphological analysis at light microscope. Naive DRG (A), caudal nerve (C), sciatic nerve (E) and
skin (G) were compared to oxaliplatin treated ones (B, D, F, H) of Balb-c mice (explanatory of the neurotoxic
damage). B: multiple (arrows) and eccentric (arrowhead) nucleoli can be observed; D and F: degenerating
fibers (arrows) and myelin derangement (arrowheads) are indicated; H: arrows point at the site of
unmyelinated fiber density reduction in the epidermis.
https://doi.org/10.1371/journal.pone.0186250.g002
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NAIVE for somatic and nucleolar areas, -10.1%, p<0.0001 vs NAIVE for nuclear area). Oxali-
platin-treated AJ, DBA/2J and CD1 mice showed significant reduction in size of 1 or 2 cellular
structures analysed while drug-treated C57BL6 mice DRG were not different from their naïve
controls (Table 3).
Morphometric analysis of unmyelinated fibers in skin biopsies. IENF density was
assessed to determine the neurotoxic injury on small fibers after oxaliplatin chronic treatment
[33–35]. The mean values (± SD) of IENF in oxaliplatin-treated groups and their naive coun-
terparts, the rate change of treated animals compared to the untreated mice and the statistical
analysis can be found in Table 3. The morphometric assessments performed on skin biopsies
Table 3. DRG and IENF morphometric analysis.
DRG SOMATIC AREA (μm2)
NAIVE OHP CHANGE vs NAIVE (%)
Balb-c 609.9 ± 15.81 533.1 ± 13.22 (**) -12.6
C57BL6 546.1 ± 14.80 542.3 ± 13.34 -0.5
AJ 584.6 ± 15.89 554.0 ± 15.33 -5.1
FVB 546.1 ± 13.85 492.8 ± 11.83 (**) -9.9
DBA/2J 631.4 ± 18.09 576.6 ± 15.61 (#) -8.7
CD1 594.2 ± 14.25 538.3 ± 14.13 (**) -9.4
DRG NUCLEAR AREA (μm2)
NAIVE OHP CHANGE vs NAIVE (%)
Balb-c 101.6 ± 1.91 89.4 ± 1.74 (***) -11.9
C57BL6 91.6 ± 1.78 89.9 ± 1.69 -1.9
AJ 97.1 ± 1.87 96.6 ± 1.83 -0.6
FVB 95.1 ± 1.94 85.6 ± 1.41(***) -10.1
DBA/2J 97.9 ± 1.90 94.8 ± 1.70 -3.5
CD1 97.2 ± 1.82 90.8 ± 1.63 (**) -6.6
DRG NUCLEOLAR AREA (μm2)
NAIVE OHP CHANGE vs NAIVE (%)
Balb-c 7.9 ± 0.21 6.77 ± 0.18 (***) -31.8
C57BL6 6.3 ± 0.16 6.25 ± 0.15 -2.2
AJ 7.2 ± 0.19 5.99 ± 0.16 (***) -17.8
FVB 8.7 ± 0.27 7.63 ± 0.18 (**) -12.9
DBA/2J 7.8 ± 0.20 6.91 ± 0.16 (**) -12.2
CD1 6.7 ± 0.17 6.77 ± 0.16 0.1
IENF (fibers/mm)
NAIVE OHP CHANGE vs NAIVE (%)
Balb-c 45.2±2.42 29.2±2.08 (**) -35.5
C57BL6 34.7±20.9 35.2±2.70 1.38
AJ 31.2±0.82 26.7±1.44 (#) -14.5
FVB 31.0±1.05 31.4±1.33 1.4
DBA/2J 35.6±1.79 29.7±1.66 (#) -24.0
CD1 27.1±1.10 23.0±1.58 (*) -15.1
The table reports the mean ± SD of the somatic, nuclear and nucleolar areas (μm2) of at least 200 sensory neurons of DRG and the linear density of IENF
expressed as mean ± SD of the unmyelinated fibers/mm in naive and oxaliplatin-treated animals of each strain. The change (%) in oxaliplatin-treated versus
respective naive animals is also reported.
DRG: #p<0.05 vs NAIVE; **p<0.001 vs NAIVE; ***p<0.0001 vs NAIVE; Student t test
IENF: **p<0.001; *p<0.01; #p<0.05 vs NAIVE; Student t test
https://doi.org/10.1371/journal.pone.0186250.t003
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of animals belonging to all mice strains demonstrated a statistically significant reduction of
IENF in Balb-c, AJ, CD1 and DBA/2J treated with oxaliplatin compared to their controls
(-35.5%, p<0.001 vs NAIVE for Balb-c; -15.1%, p<0.01 vs NAIVE for CD1; -14.5%, p<0.05 vs
NAIVE for AJ and –24%, p<0.05 vs NAIVE for DBA/2J) (Table 3).
Neuropathic pain assessment
Dynamic test for mechanical allodynia. As widely observed in cancer patients and repro-
duced in a few animal models [1, 36], oxaliplatin treatment causes peripheral neurotoxicity,
and neuropathic pain after chronic treatments. To determine whether our strains of mice dif-
ferently exhibit changes in the sensory threshold, animals were tested for mechanical sensitiv-
ity. Mice were tested at baseline (day 1), 24 hours after the 4th (day 13) and the 8th oxaliplatin
injection (day 26). Mice in all strains showed a decrease in the withdrawal response (grams)
during a non-noxious punctate mechanical pressure on the surface of the hind paw both at
day 13 and 26 (mechanical allodynia), with a different statistical significance. Twenty-four
hours after the last oxaliplatin injection Balb-c, C57BL6, AJ, FVB, DBA/2J and CD1 mice
reached respectively a 19%, 14.3%, 24%, 9.2%, 19.5% and 18.9%-significant decrease in their
mechanical threshold compared to their respective naive animals (p<0.001 vs NAIVE for
Balb-c; p<0.01 vs NAIVE for AJ, DBA/2J and CD1; p<0.05 vs NAIVE for C57BL6 and FVB)
(Fig 3).
Electrophysiological analysis of wide dynamic range (WDR) neurons in the spinal dor-
sal horn. It was previously demonstrated that oxaliplatin is able to induce physiological
changes in the primary afferents as well as in the spinal cord dorsal horn WDR neurons in
Balb-c mice [1]. WDR neurons produces an electrical response to innocuous (i.e brush), nox-
ious (i.e press) and thermal (i.e. acetone) stimulation applied to the plantar surface of the hind
paw ipsilateral to the recording site in the spinal cord. It is hypothesized that, after the expo-
sure to oxaliplatin, increased excitatory activity of central neurons is secondary to peripheral
sensitization of primary afferents.
Twenty-four hours after the last oxaliplatin dose, cohorts of dedicated mice underwent the
surgical procedure to expose the spinal cord lumbar segment. The activity was recorded from
a mean of 15 WDR neurons/animal from 10 animals/group. The mean values (± SD) of the
number of spikes/second recorded during 10 seconds stimulation with brush, 2 seconds stimu-
lation with press and 2 seconds stimulation with cold acetone in oxaliplatin-treated animals
and in their naive counterparts, the rate change of treated animals compared to the untreated
mice and the statistical analysis can be found in S2 Table.
In agreement with the results of the behavioural tests, oxaliplatin-treated Balb-c and AJ
mice (that were particularly affected by mechanical allodynia and acute cold thermal hyperal-
gesia) showed a number of spikes significantly higher during stimulation with the innocuous
brush (Balb c:+40.2% p<0.05 vs NAIVE; AJ +238%, p<0.0001 vs NAIVE), the moderately
noxious press (Balb-c +102%, p<0.05 vs NAIVE; AJ: +119%, p<0.01 vs NAIVE) and the cold
acetone (Balb-c: +93.4%, p<0.05 vs NAIVE; AJ: +297%, p<0.001 vs NAIVE). FVB animals
that developed acute cold hyperalgesia 24 hours after the last oxaliplatin treatment and
mechanical allodynia did not show any sign of increased spinal dorsal horn neuronal activity
during mechanical stimulations, but had a significant increase in the number of spikes/second
during the cold thermal stimulation with acetone (+132%, p<0.05 vs NAIVE). C57BL6 mice,
which showed only mechanical allodynia, had increased spinal dorsal horn neuronal activity
with both the innocuous brush and cold acetone (+44%, p<0.05 vs NAÏVE and (+111%,
p<0.01 vs NAÏVE, respectively).
All the results reported so far are summarized in Table 4.
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Fig 3. Dynamic test. The graphs report the pressure (grams) evoking a withdrawal response during mechanical stimuli of
oxaliplatin-treated animals versus naive animals at baseline, day 13 and day 26.
https://doi.org/10.1371/journal.pone.0186250.g003
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Platinum concentration
Platinum concentration was measured by atomic absorption 72 hours after the last oxaliplatin
injection in DRG, sciatic nerves and plasma of oxaliplatin-treated animals of each strain. Plati-
num concentration in plasma was similar, but irrelevant in all strains confirming that the drug
clearance was almost completed within 48 hours. The concentration of platinum stored in
DRG and sciatic nerves was very high in all the strains considered. The mean amount of plati-
num measured in the DRG of AJ mice was significantly higher compared to Balb-c (p<0.05 vs
AJ), C57BL6, FVB and DBA/2J (p<0.001 vs AJ). No statistically significant differences between
strains were detected in the sciatic nerves.
The data on platinum concentration can be found in S3 Table.
Gene expression evaluation
We then performed microarray analysis of DRG from AJ, CD1, Balb-c and C57BL6 mice to
evaluate gene expression changes. Analysis was performed comparing gene expression changes
among samples from treated and untreated animals. We included in the analysis only genes
with an average expression greater than 6 (log2 Intensity values) and showing a |log2FC| > 0.5,
as lower expressions are, in our experience, unreliable. Eight genes were significantly up-regu-
lated and 14 were significantly down-regulated in Balb-c-treated animals, 3 genes were up-reg-
ulated and 11 were down-regulated in AJ-treated animals, 1 gene was up-regulated and 4
Table 4. Summary of the results of neurotoxicity studies.
STRAINS
Balb-c C57BL6 AJ FVB DBA/2J CD1
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The table summarizes the results of the statistical analysis performed on each parameter evaluated to assess the severity of peripheral neuropathy and
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genes were down-regulated in CD1-treated mice. No genes were significantly changed in
C57BL6. This last observation, surprisingly, contrasts with the significant effect of OHP on
mechanical allodynia and WDR neurons in the spinal cord. Most genes were differentially
expressed in a single mouse strain although some common features were observed (Table 5, S1
Fig). Most changes were of moderate intensity although CD74 and H2-Eb1 in Balb-c and
H2-Ab1 in CD1 showed log2 fold changes greater than 2. All other changes showed a log2
fold-change of about 1.
The observation that different genes were modified by oxaliplatin in the different mouse
strains, together with the small changes observed, led us to hypothesize that the protocol
employed possibly had low statistical power to determine small-to-medium-changes and that
variability within samples of the same strain also was a confounding factor. This hypothesis,
together with the complex behavioural phenotypes described above, prevented us from corre-
lating single genes to single observations.
To circumvent in part these limitations, we next decided to perform a supervised analysis
of the results, independently of statistical significance, as a pilot investigation. Again, we
included in the analysis only genes with an average expression greater than 6 (log2 Intensity
values). Secondly, we extracted only those genes that the microarray projected as doubling or
halving their levels upon treatment (a logFC >1 or <-1) in at least one strain. This led to a
total of 122 up-regulated genes and 103 down-regulated genes (S4 Table).
As can be observed from the Venn diagram (S1 Fig), genes were again modulated differ-
ently in the different strains. However, we felt that, while of possible interest, the lack of statis-
tical significance for most of these genes and the post-hoc nature of this analysis did not allow
us to turn our attention to single genes that displayed a different behaviour in the different
strains.
On the contrary, we felt that the 8 genes with a fold-change of logFC>1 (Tnnc2, Myl1,
Pgam, Myh8, Tnni2, Tnnt3 v1) or <-1 (H2-Eb1, CD74) in all 4 strains deserved further atten-
tion. Furthermore, we implemented the list with a further 12 genes in which this fold-change
was verified in at least 2 strains and was> 0.5 (Myh4, Tcap, Cox6a2, Tnnt3 v7, Acta1, Mb v2,
Myl2, Ckm, Myl1 v3, Mybpc2) or<-0.5 (H2-Ab1, Siglech) in the other 2 strains. Due to the
heuristic nature of the pure logFC criterion, we decided to support the selection of the com-
mon differentially regulated genes by means a statistically rigorous approach known as the
rank product method. This algorithm, firstly reported by Breitling et al. 17 and Heskes et al. 18
is a non-parametric statistical test based on ranks of FC (or logFC) expression values. The pro-
cedure (S1 File), validated the former logFC-based gene list. We implemented, as a control,
this list with the 8 genes with |log2FC|>1 that had shown significant statistical changes in one
mouse strain but that were not included in the above list as a trend of change was not observed
in the other mouse strains.
First, we used these genes to confirm whether the data from the microarray experiments
were reliable, validating them using a different set of treated and untreated tissues and analys-
ing the relative abundance of the genes by RT-PCR. A gross analysis of the results revealed a
good correlation between the data obtained by microarray and the data obtained by RT-PCR
(Fig 4). This showed, therefore, that the changes observed in the microarrays could be grossly
replicated by other methods. This was confirmed by the fact that when analysing the single
genes that had met the criteria above, 15 out of the 20 analysed transcripts were confirmed to
increase or decrease of at least 1.5-fold compared to control untreated tissues in all 4 strains
(Table 6). On the other hand, only 1 of the 8 genes (Ctse) that had shown statistical significance
in a single strain, but that had not met the above criteria, met the criteria in the four strains in
RT-PCR experiments.
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Table 5. List of genes that displayed significant changes between treated and untreated mice.
Balb-c
ProbeName GeneSymbol p-values adj.p-values log_FC AveExpr
Up-regulated A_55_P1987499 Pttg1 0.000000 0.001638 1.136716 11.216251
A_55_P1959500 Ces2e 0.000001 0.003382 1.102319 6.898396
A_55_P1965154 Spc25 0.000037 0.043139 0.722801 8.389159
A_51_P457528 Ccnb2 0.000047 0.047962 0.702836 7.729787
A_55_P1960735 Gdf15 0.000000 0.000146 0.606808 6.644995
A_51_P246339 Rfc5 0.000044 0.047510 0.520725 9.200125
A_51_P455897 Fam64a 0.000024 0.036096 0.505713 6.398450
Down-regulated A_51_P223498 Slc39a10 0.000023 0.036096 -0.556914 8.941834
A_66_P109002 Kcng2 0.000011 0.025093 -0.801808 8.403939
A_51_P222741 H2-Ea-ps 0.000000 0.000000 -0.869288 6.206409
A_52_P99810 Cx3cr1 0.000002 0.011096 -0.881694 7.221797
A_55_P1964363 Kctd14 0.000030 0.040871 -0.914326 8.966172
A_55_P2104412 Gm10081 0.000038 0.043139 -0.997577 6.375892
A_52_P574274 Spatc1 0.000000 0.002257 -1.093003 6.606756
A_55_P2165790 Siglech 0.000000 0.000247 -1.106950 6.821341
A_52_P1135722 Gm684 0.000014 0.027716 -1.277763 6.766403
A_51_P278868 H2-DMb1 0.000000 0.000212 -1.279237 9.457730
A_55_P1962747 H2-Ab1 0.000001 0.003914 -1.578391 11.720059
A_55_P2146560 H2-Ab1 0.000000 0.001134 -1.709102 11.478677
A_55_P2156731 H2-Eb1 0.000000 0.000064 -2.241588 11.624532
A_51_P284608 Cd74 0.000000 0.000135 -2.477466 10.681315
AJ
ProbeName GeneSymbol p-values adj.p-values log_FC AveExpr
Up-regulated A_55_P1976694 Sept11 0.000013 0.040107 0.650315 9.273354
A_55_P2141013 Siglech 0.000000 0.002661 0.636849 15.720079
A_55_P1982737 Dnajc5 0.000005 0.022082 0.571697 15.771884
Down-regulated A_51_P370678 Gfi1b 0.000015 0.040107 -0.521881 6.599796
A_55_P2153382 Ermap 0.000002 0.014967 -0.530305 6.268419
A_55_P2082929 H2-Ob 0.000011 0.040107 -0.633375 6.475577
A_51_P231320 Mmp8 0.000015 0.040107 -0.819533 6.533332
A_55_P2091551 Arhgap9 0.000010 0.040107 -0.824860 8.352636
A_51_P194609 Prss34 0.000001 0.011873 -0.871312 6.516110
A_51_P391716 Ermap 0.000001 0.011873 -0.911140 6.493820
A_55_P1997126 Ctse 0.000002 0.014967 -1.045790 6.492716
A_51_P299062 Kel 0.000001 0.011873 -1.205625 6.585137
A_55_P2165790 Siglech 0.000003 0.021889 -1.408224 7.074684
A_51_P241769 Rhd 0.000000 0.002661 -1.420892 6.805098
CD1
ProbeName GeneSymbol p-values adj.p-values log_FC AveExpr
Up-regulated A_51_P168792 Xylb 0.000007 0.041672 0.544057 8.731946
Down-regulated A_51_P496804 Adat2 0.000004 0.034816 -0.845346 9.166717
A_51_P284608 Cd74 0.000001 0.021062 -2.443737 10.825574
A_55_P1962747 H2-Ab1 0.000000 0.000022 -2.641439 11.335051
A_55_P2146560 H2-Ab1 0.000000 0.000029 -3.123013 10.931527
https://doi.org/10.1371/journal.pone.0186250.t005
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Second, we verified if any of the above genes were increased or decreased of at least 1.5-fold
compared to control untreated tissues in all 6 strains (Table 6). This led to four genes (Tnnc2,
MyH4, CD74 and Siglech) that showed changes in all the strains evaluated. Of the two strains
added to this analysis, DBA/2J was the one that showed more profound differences in gene
expression changes compared to the other strains. Indeed, 11 out of 15 genes showed similar
trends in the five strains, excluding DBA/2J.
Discussion
Oxaliplatin ((1R,-2R)-1,2-cyclohexanediamine-N,N’][oxalato (2—)-O,O’]platinum) is a third
generation platinum compound discovered in 1976 and approved by the Food and Drug
Administration in 2004 for the treatment of advanced colorectal cancer (http://www.fda.gov/
Drugs/DrugSafety/PostmarketDrugSafety). Its therapeutic spectrum was later extended to
other malignancies [13]. Subsequently, its efficacy in adjuvant settings (combined with leucov-
orin and 5-fluorouracil) has also been established leading to an increased number of colorectal
cancer patients receiving oxaliplatin. Its clinical use is limited by the onset in patients of 2 clini-
cally distinct forms of peripheral neurotoxicity: a transient and acute syndrome appearing dur-
ing or shortly after the infusion (affecting up to 95% patients) and a chronic dose-limiting
cumulative sensory neuropathy (up to 40–80% of patients) [2].
The risk of developing OIPN is related to several factors including cumulative dose, demo-
graphics and co-morbidities. However, the susceptibility to OIPN differs also among patients
with similar history and therapeutic regimens suggesting that individual genetic variability can
influence the drug neurotoxic response.
To mimic the clinical heterogeneity observed in clinical practice, we employed 6 genetically
different mice strains with the aim to evaluate the influence of a different genetic background
Fig 4. Correlation of the log-change of the 30 selected genes in the 4 strains as predicted by microarray analysis and RT-PCR.
https://doi.org/10.1371/journal.pone.0186250.g004
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in determining OIPN phenotypic features. Ten-week-old male mice belonging to Balb-c,
C57BL6, AJ, FVB, DBA/2J, CD1 strains were exposed to a well-established chronic schedule of
oxaliplatin able to induce a neurotoxic damage without threaten mice general health [1] and
tested for the development of peripheral neurotoxicity and neuropathic pain. Moreover, the
cumulative dose of oxaliplatin we administered in mice (equivalent to 1080 mg/m2) was in the
same range of dosage reported to be neurotoxic in patients [37–39].
The set of outcome measures was selected in order to ascertain the severity of the nervous
system damage along the entire sensory pathway (i.e. from the distal nerve endings in the skin
up to the spinal dorsal horn wide dynamic range neurons). This was performed with neuro-
physiological and morphological/morphometric methods as well as with the evaluation of the
painful features of peripheral neuropathy at the behavioural level using cold hypersensitivity
Table 6. Genes evaluated in RT-PCR experiments.
C57BL6 Balb-c AJ CD1 DBA/2J FVB
Tnnc2 31.00±0.47 2.13±0.62 4.25±0.43 5.6±0.47 4.31±0.27 3.75±0.06
Myl1 3.13±0.51 4.13±0.63 5.85±0.76 4.69±0.98 1.38±0.29 4.03±0.36
Pgam 2.02±0.65 1.34±0.41 2.39±0.43 2.83±0.34 1.66±0.19 16.36±0.66
Myh8 12.87±0.99 4.39±0.39 3.74±0.14 4.00±0.63 0.34±0.08 1.38±0.33
Tnni2 1.63±0.28 7.94±0.25 2.09±0.34 23.02±0.55 0.59±0.11 0.36±0.099
Tnnt3 v1 5.85±0.86 1.39±0.93 2.05±0.51 2.28±0.51 1.17±0.21 0.91±0.068
H2-Eb1 (a) 0.095±0.0063 0.15±0.02 0.29±0.03 0.12±0.006 0.91±0.036 0.18±0.012
CD74 (b) 0.11±0.04 0.17±0.06 0.04±0.006 0.0044±0.001 0.03±0.001 0.10±0.06
Myh4 4.94±0.97 2.2±0.50 9.19±0.29 6.34±0.38 3.76±0.56 3.39±0.12
Tcap 1.74±0.45 4.44±0.52 7.59±0.45 3.32±0.60 0.20±0.001 3.04±0.55
Cox6a2 1.94±0.65 1.52±0.01 2.86±0.79 4.81±0.43 2.34±0.67 0.99±0.034
Tnnt3 v7 2.06±0.86 136.87±0.37 3.09±0.46 5.65±0.47 0.98±0.05 2.62±0.38
Acta1 2.34±0.58 4.12±0.97 3.53±0.42 2.24±0.42 0.07±0.03 2.79±0.44
Mb v2 3.92±0.45 3.76±0.98 1.90±0.55 4.08±0.59 0.18±0.017 3.26±0.14
Myl2 1.78±0.61 51.98±0.71 1.16±0.004 1.59±0.40 0.08±0.004 2.31±0.17
Ckm 4.66±0.058 24.45±0.39 5.32±0.56 2.60±0.56 1.33±0.23 1.04±0.098
Myl1 v3 1.04±0.12 2.04±0.36 3.45±0.36 1.68±0.61 1.00±0.012 0.77±0.045
Mybpc2 2.35±0.25 4.00±1.05 2.74±0.29 1.24±0.46 0.70±0.2 1.52±0.078
H2-Ab1 (b) 0.24±0.003 0.15±0.0002 0.17±0.035 0.05±0.0001 0.86±0.47 0.22±0.071
Siglech (c) 0.70±0.12 0.13±0.02 0.19±0.032 0.25±0.07 0.18±0.08 0.17±0.067
Ctse (d) 0.67±0.36 0.59±0.08 0.025±0.08 0.58±0.057 5.45±0.95 0.73±0.068
Pttg1 (a) 1.06±0.10 1.72±0.47 0.73±0.061 9.04±1.93 5.14±0.94 0.63±0.039
Gm684 (a) 1.94±0.16 0.54±0.077 0.81±0.067 0.57±0.016 1.32±0.26 0.75±0.021
Rhd (d) 1.56±0.52 1.19±0.11 0.05±0.004 1.20±0.017 0.81±0.055 0.33±0.018
Spatc1 (a) 0.30±0.27 0.26±0.045 1.19±0.21 0.81±0.065 0.56±0.066 0.73±0.042
H2-DMb1 (a) 0.10±0.037 0.58±0.05 0.01±0.016 0.89±0.075 0.72±0.029 0.96±0.023
Kel (d) 0.69±0.062 1.04±0.17 0.03±0.002 0.85±0.041 0.61±0.075 0.23±0.034
Ces2e (a) 0.69±0.021 9.69±0.61 4.10±0.98 4.60±1.038 0.89±0.058 6.03±1.36
Genes evaluated in RT-PCR experiments in all 6 mouse strains on DRG tissues distinct from those used for microarray experiments. Values express fold-
change and are mean + S.E.M. Each group was composed of 6 samples and were analysed in triplicate.
(a) refers to genes that were found significantly changed in Balb-c in microarray experiments;
(b) refers to genes that were found significantly changed in Balb-c and CD1 in microarray experiments;
(c) refers to genes that were found significantly changed in Balb-c and AJ in microarray experiments;
(d) refers to genes that were found significantly changed in AJ in microarray experiments.
https://doi.org/10.1371/journal.pone.0186250.t006
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assessed 24 hours after drug delivery as an indicator of acute neurotoxicity and mechanical
threshold as a marker of chronic neurotoxicity. In view of the results previously obtained in
Balb-c mice [1] the assessment of nocifensive behaviours was associated with the measurement
of WDR spinal dorsal horn electrical activity to evaluate the occurrence of hyperexcitability in
response to both noxious (press) and non-noxious (brush) tactile and thermal (acetone)
stimuli.
As a general consideration, all mice strains (irrespectively to be inbred or outbred) devel-
oped some degree of OIPN, although remarkable differences were observed in its severity and
in the specific features, thus supporting the hypothesis that a genetic component might be rele-
vant in this experimental setting and mimicking the clinical situation. Also, it was quite inter-
esting that the parameters measured were not strictly correlated, with strains displaying only
selected features over others (Table 4). Outbred strain (CD1) did not show distinct features in
comparison to inbred strains.
Overall, mechanical allodynia was significantly present in all 6 strains (albeit to different
levels), but this was not true for cold hyperalgesia. This suggests that the molecular mecha-
nisms behind these phenomena are distinct and that the selection of the read-out in the differ-
ent strains might influence the interpretation of the effects of oxaliplatin administration. These
observations, in our opinion, must serve as a warning when devising pre-clinical models to
develop new drug treatments.
Balb-c and FVB were the most severely affected strains, with clear damage of all the sensory
peripheral nervous system structures investigated associated to acute and chronic nocifensive
behaviour. By contrast, C57Bl6 and AJ strains developed a nocifensive behaviour (but only AJ
mice showed a robust acute cold allodynia) and different degrees of WDR neurons hyper-
excitability with minimal or no evidence of somatic neurotoxicity. DBA/2J and CD1 mice
tended to show the opposite results, i.e. only mechanical allodynia in the context of nerve and
DRG damage demonstrated with neurophysiological and pathological methods (Table 4).
The differences we described above did not correlate to the quantity of oxaliplatin accumu-
lated in DRGs and sciatic nerves. Moreover, it is very likely that the concentrations of platinum
measured after 8 injection of oxaliplatin is abundantly higher than those needed to induce a
neurotoxic damage in all the strains considered. Therefore, we do not consider the statistical
differences observed between strains in the DRG to be biologically and functionally
significant.
This is the first comprehensive pre-clinical study aimed at the comparison of the suscepti-
bility to oxaliplatin peripheral neurotoxicity of different mice strains and, therefore, our results
are not thoroughly comparable with literature data. Only data regarding Balb-c mice can be
compared with previously reported studies in which this strain was largely employed. As we
also confirmed in this study, Renn and collaborators described the development of somatic
and painful peripheral neurotoxicity in Balb-c mice treated with a chronic schedule of oxalipla-
tin [1]. Similar functional alterations of the peripheral nerves were observed also by Wozniak
and collaborators in Balb-c mice [40] while exposing animals to a higher treatment regimen
close to the maximal tolerated dose (6 mg/Kg twice weekly for 4 weeks). Conversely, our
results cannot be compared to numerous other toxicity studies in which oxaliplatin was
injected repeatedly for few consecutive days in order to induce nocifensive behaviours [41–
43], since it is very unlikely that these schedules can also induce a chronic neurotoxic damage
in the peripheral nervous system. However, partial considerations can be done evaluating our
results with those of other groups demonstrating that different mice strains can differently
respond to other neurotoxic chemotherapy drugs, such as paclitaxel, bortezomib and cisplatin.
Smith and colleagues [20] exposed male and female mice belonging to 10 inbred strains to the
same short and low dose paclitaxel schedule (0.1 mg/ml, i.p., on 4 alternate days) observing the
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development of mechanical allodynia with different intensity and severity suggesting a geno-
type-dependent pattern of responses. DBA/2J and C57BL6 respectively showed a higher and a
lower response to paclitaxel treatment. Authors hypothesised, without providing any experi-
mental evidence for their hypothesis, that a common set of genes was responsible for the vari-
ability. More recently, Podratz and collaborators found differences in other chemotherapy-
induced neurotoxicities between rodent strains using in vitro systems [19]. Cultured DRG
from C57BL6 and Balb-c mice exposed to increased concentration of cisplatin (1, 5, 10,
50 μg/ml) were more sensitive than those from DBA/2J and C3H/HeJ. Bortezomib at concen-
trations of 25, 50, 100, 200 nM induced a biphasic dose response in DBA/2J and C3H/H3J
mice. However, C57BL6 DRG and Balb-c DRG were respectively the most and least sensitive
to bortezomib [19]. Finally, we observed that the development of mechanical allodynia and the
impairment of neurophysiological functions were significantly different across strains (Balb-c,
C57BL6, AJ, FVB, DBA/2J, CD1) following chronic cisplatin treatment at the dose of 4 mg/Kg
twice weekly for 4 weeks (personal observation).
In addition to our extensive characterization, we also performed a gene microarray analysis
of DRG to investigate differences in gene expression. Surprisingly, the observed very high plat-
inum concentration found in DRG did not induce huge changes in gene expression. While
some changes were statistically significant, it was evident that only small-to-medium changes
occurred. A first observation of our investigation is that some changes occur only in single
mouse strains, and this was confirmed by RT-PCR analysis of different samples. Again, this
warrants for attention when evaluating single models of OIPN. We also decided to highlight
those changes that were evident in all 6 strains in order to gain pilot information for future
investigations. The genes that were changed in all 4 strains were unexpected. First, the treated
animals showed an enrichment in troponins (Tnnc2) and myosins (MyH4). Tnnc2 and MyH4
showed an increase in all six strains, including DBA/2J and FVB, when tested by RT-PCR but
it should be noted that other troponins and myosins also were increased in most strains
(Tnnt3v1, Tnnt3v7, TnnI2, MyH8, MyL1, MyBPC2, MyL2, and MyL1v3) Indeed, a literature
search did show that troponins 27,28 and myosins 28–31 are present in DRG 27,31 and that others
had identified these as up-regulated in this tissue in neuropathic models 32. The role of tropo-
nins, that our arrays suggest to be expressed in moderate to high levels in DRG, has not been
investigated to our knowledge, while a number of reports indicate that myosins are involved in
growth cone responses 30 and generation of filopodia and lamellipodia 33. Whether this is a
compensatory effect of the oxaliplatin insult or whether these changes participate in the dam-
age remains to be ascertained.
The 2 down-regulated proteins were equally surprising, as they were a sialic acid binding
Ig-like lectin H (Siglech) and CD74. It should be noticed that type-2 histocompatibility com-
plexes (H2-Ab1 and H2-Eb1: MHC) were also significantly decreased in most mouse strains,
except for DBA/2J. MHC class II genes have been previously shown to be up-regulated in
DRG in models of peripheral nerve injury 34,35. It has been suggested that this increase is corre-
lated with invasion of the DRGs by peripheral MHC+ macrophages 36. In our model, the fact
that MHC class II genes are decreased might instead signify that there is a selective injury to
MHC class II+ cells by oxaliplatin although other explanations are possible. CD74 is an extra-
cellular surface receptor for macrophage migration inhibitory factor and therefore it is not sur-
prising that it correlates with a decrease in MHC-type II genes. A different involvement of the
macrophage component in OIPN compared to other peripheral neuropathies would obviously
be of great importance but needs confirmation with other approaches. Again, it remains to be
ascertained whether these would be compensatory mechanisms or a root cause of the damage.
The above data altogether suggest that the four identified genes should be the focus of fur-
ther investigation in the context of OIPN. Particular attention should be devoted to CD74 and
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Siglech, which were both formally identified via stringent adjusted statistical significance in
two strains and by supervised analysis in all six strains. Furthermore, the data also suggest
novel study designs that should overcome in the future some of the limits of our approach.
First, it is apparent from the nature of the identified genes that the cell origin of these changes
might be non-neuronal. While this opens new scenarios on how OIPN might be triggered (for
example, with an involvement of satellite cells), it also sets a confounding factor, given that sat-
ellite cells, infiltrating cells and connective tissue might be dominant over sensory neurons.
Future experiments should undertake microarray experiments on sorted isolated cells (both
neuronal and non-neuronal) to unravel the origin of the oxaliplatin-induced changes and to
identify neuronal changes as well. Second, the microarray experiments were not performed on
the same animals that underwent the behavioural/electrophysiological/histological tests and
therefore we cannot reconcile the single genotype to the single phenotype. Given the intra-
strain variability that we observed future behavioural and microarray experiments should be
performed on the same animals, as this would allow to compare highly sensitive and less sensi-
tive mice on parameters that are relevant to human disorder (e.g. nerve conduction).
Conclusions
In conclusion, this work demonstrated that different mice strains, exposed to the same oxali-
platin treatment, do have different neurotoxic phenotypes. This is of particular interest in
choosing the most appropriate strain to be employed, based on the selected read-out parame-
ter in the neurotoxicity study. Similar conclusions were obtained when evaluating gene
expression changes induced by oxaliplatin in whole DRGs. Moreover, the genetic analysis
demonstrated that oxaliplatin determines small-to-medium gene expression changes. Not-
withstanding the above considerations, the expression of CD74 and Siglech was reduced in
all strains considered, suggesting that common features exist.
Our approach, and the genes highlighted, also suggest that alongside investigating the role
of these genes, future work should be directed at (i) investigating gene expression changes in
isolated DRG populations (to dissect the neuronal and non-neuronal cells) and (ii) performing
microarray analysis on the same animals that undergo phenotypic evaluation, to better corre-
late gene expression changes to phenotypic characteristics, bypassing intra-strain variability.
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